StockData
uniQure N.V. logo

uniQure N.V. (QURE) shareholders

QURENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30224% above fair value
$20.30−0.48 (-2.31%)

Close on Nov 18, 2026Market cap $1.41BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
96.0%
67M of 69M shares
Institutional holders
254
91 new, 48 sold out
Net institutional buying
6M
In Q2 2026
Insider trades, 12 months
0 buys · 53 sales
Net sold $20.23M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Avoro Capital Advisors LLC
Joint filing with Behzad Aghazadeh (9.87%)
6,150,0009.87%13G (passive) amendmentDec 31, 2025
FMR LLC
Joint filing with Abigail P. Johnson (9.80%)
6,059,5749.80%13G (passive)Sep 30, 2025
JPMorgan Chase & Co.5,951,7948.50%13G (passive) amendmentSep 30, 2026
JPMorgan Chase & Co4,866,2117.00%13G (passive)Jun 30, 2026
Vestal Point Capital, LP
Joint filing with Ryan Wilder (8.90%)
4,792,5728.90%13G (passive) amendmentMar 31, 2025
Roderick Wong, M.D.
Joint filing with RTW Investments, LP (7.90%)
4,265,4287.90%13G (passive)Mar 31, 2025
RTW Investments, LP
Joint filing with Roderick Wong (5.70%)
3,941,5725.70%13G (passive)Jun 30, 2026
Roderick Wong
Joint filing with RTW Investments, LP (6.00%)
3,711,4626.00%13G (passive) amendmentDec 31, 2025
Aberdeen Group plc
Joint filing with abrdn Inc. (5.91%)
3,678,6405.91%13G (passive) amendmentDec 31, 2025
Behzad Aghazadeh
Joint filing with Avoro Capital Advisors LLC (6.60%)
3,625,0006.60%13G (passive)Jun 30, 2025
SIG Brokerage, LP
Joint filing with G1 Execution Services, LLC (5.70%), Susquehanna Portfolio Strategies, LLC (5.70%) and 1 more
3,536,4855.70%13G (passive)Dec 31, 2025
Nantahala Capital Management, LLC
Joint filing with Wilmot B. Harkey (6.12%), Daniel Mack (6.12%)
2,982,0136.12%13G (passive) amendmentSep 30, 2024
Joe Lewis
Joint filing with This Schedule 13G is jointly filed by Boxer Capital, LLC (“ Boxer Capital ”), Boxer Asset Management Inc. (“ Boxer Management ”) and Joe Lewis (collectively, the “ Reporting Persons ”). Boxer Manageme (5.10%), Boxer Asset Management Inc. (5.10%)
2,500,0005.10%13G (passive)Jul 10, 2024

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of QUREValueChange% of portfolio
Avoro Capital Advisors LLC6,727,7779.70%$309.88M+768,1822.78%
JPMorgan Chase & Co4,867,7557.02%$230.81M+2,030,2890.01%
Rtw Investments, LP3,941,5725.68%$181.55M+1,355,2161.55%
State Street Corp2,903,8254.19%$133.75M+643,3130.00%
abrdn plc2,848,1174.11%$131.18M−2,458,2690.18%
BlackRock, Inc.1,877,4532.71%$86.48M+143,9950.00%
Orbimed Advisors LLC1,807,4862.61%$83.25M−328,6631.54%
Jane Street Group, LLC1,610,4832.32%$74.18M+974,4880.01%
Jennison Associates LLC1,561,4122.25%$71.92M+327,6230.04%
Boxer Capital Management, LLC1,503,3002.17%$69.24M+841,3005.21%
Goldman Sachs Group Inc1,475,9562.13%$67.98M+212,7200.01%
Two Sigma Investments, LP1,462,0242.11%$67.34M−1,213,8470.05%
Two Seas Capital LP1,441,4102.08%$66.39M+141,4101.31%
FMR LLC1,270,0681.83%$58.50M−473,7400.00%
Mak Capital One LLC1,232,0511.78%$56.75M+790,8467.95%
Mpm Bioimpact LLC1,225,8551.77%$56.46M−143,3763.44%
Morgan Stanley1,066,6391.54%$49.13M+700,5220.00%
Assenagon Asset Management S.A.1,027,0601.48%$47.31M+880,3110.03%
Vestal Point Capital, LP935,0001.35%$43.07M+576,0041.01%
Maverick Capital Ltd925,3831.33%$42.62M+227,7430.38%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202625467M96.0%91 / 8659 / 4821M15M
Q1 202621360M86.7%47 / 7261 / 5217M18M
Q4 202522662M89.3%73 / 7361 / 6323M17M
Q3 202521957M81.6%97 / 4961 / 2020M17M
Q2 202514353M76.9%32 / 4249 / 3012M9M
Q1 202514150M72.3%24 / 5437 / 2015M6M
Q4 202413842M60.1%36 / 3548 / 2715M13M
Q3 202413139M56.8%32 / 3640 / 1615M9M
Q2 202411735M50.6%18 / 3637 / 336M8M
Q1 202413237M52.7%19 / 5233 / 308M14M
Q4 202314443M62.3%28 / 4455 / 4215M7M
Q3 202316036M52.2%32 / 6044 / 4613M11M

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Matthew C. KapustaCEO, Managing Director531,1090.77%Jul 7, 2026
Walid Abi-SaabChief Medical Officer166,9850.24%Nov 3, 2026
Jeannette PottsChief Legal Officer133,2460.19%Jun 17, 2026
Kylie O'KeefeChief Customer & Strat Officer108,8640.16%Jun 12, 2026
Christian KlemtChief Financial Officer238,5810.34%Mar 6, 2026
David D. MeekDirector30,6670.04%Nov 10, 2026
Jack KayeDirector43,0560.06%Jul 2, 2026
Madhavan BalachandranDirector49,6440.07%Jun 22, 2026
Leonard E. PostDirector35,4940.05%Jun 12, 2026
Robert GutDirector32,2590.05%Jun 12, 2026
Jeremy P. SpringhornDirector43,2510.06%Jun 12, 2026
Rachelle Suzanne JacquesDirector33,9030.05%Jun 12, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
David D. Meek
Director
Nov 6, 2026Sale(10b5-1 plan)−9,080$21.25$192.95K30,667
Walid Abi-Saab
Chief Medical Officer
Oct 30, 2026Award+18,750––166,985
Matthew C. Kapusta
CEO, Managing Director
Jul 2, 2026Sale(10b5-1 plan)−9,200$44.43$408.76K531,109
Matthew C. Kapusta
CEO, Managing Director
Jul 2, 2026Sale(10b5-1 plan)−4,282$45.43$194.53K526,827
Matthew C. Kapusta
CEO, Managing Director
Jul 2, 2026Sale(10b5-1 plan)−7,600$45.89$348.76K519,227
Matthew C. Kapusta
CEO, Managing Director
Jul 2, 2026Option exercise+21,082$19.39$408.78K540,309
Walid Abi-Saab
Chief Medical Officer
Jun 30, 2026Sale(10b5-1 plan)−10,000$46.46$464.60K168,235
Walid Abi-Saab
Chief Medical Officer
Jun 30, 2026Sale(10b5-1 plan)−20,000$46.40$928.00K148,235
Walid Abi-Saab
Chief Medical Officer
Jun 30, 2026Option exercise+10,000$5.59$55.90K178,235
Jack Kaye
Director
Jun 30, 2026Option exercise+17,060$20.18$344.27K43,056
Jack Kaye
Director
Jun 30, 2026Sale(10b5-1 plan)−4,107$46.49$190.93K25,996
Jack Kaye
Director
Jun 30, 2026Option exercise+4,107$37.00$151.96K30,103
Jack Kaye
Director
Jun 30, 2026Sale(10b5-1 plan)−17,060$46.43$792.10K25,996
Walid Abi-Saab
Chief Medical Officer
Jun 26, 2026Sale−1,434$46.86$67.20K168,235
Matthew C. Kapusta
CEO, Managing Director
Jun 25, 2026Sale(10b5-1 plan)−28,716$50.02$1.44M519,227
Matthew C. Kapusta
CEO, Managing Director
Jun 25, 2026Option exercise+28,716$31.71$910.58K547,943
Matthew C. Kapusta
CEO, Managing Director
Jun 24, 2026Option exercise+4,128$31.71$130.90K525,923
Matthew C. Kapusta
CEO, Managing Director
Jun 24, 2026Sale(10b5-1 plan)−6,696$50.00$334.80K519,227
Matthew C. Kapusta
CEO, Managing Director
Jun 18, 2026Option exercise+4,656$31.71$147.64K563,466
Matthew C. Kapusta
CEO, Managing Director
Jun 18, 2026Sale(10b5-1 plan)−4,656$50.00$232.80K558,810
Matthew C. Kapusta
CEO, Managing Director
Jun 18, 2026Sale(10b5-1 plan)−37,015$50.00$1.85M521,795
Jack Kaye
Director
Jun 17, 2026Sale(10b5-1 plan)−5,295$42.57$225.41K25,996
Jack Kaye
Director
Jun 17, 2026Option exercise+5,295$31.71$167.90K31,291
Matthew C. Kapusta
CEO, Managing Director
Jun 17, 2026Sale(10b5-1 plan)−56,929$43.43$2.47M603,729
Matthew C. Kapusta
CEO, Managing Director
Jun 17, 2026Sale(10b5-1 plan)−6,023$43.70$263.21K693,239
Matthew C. Kapusta
CEO, Managing Director
Jun 17, 2026Sale(10b5-1 plan)−23,977$42.61$1.02M699,262
Matthew C. Kapusta
CEO, Managing Director
Jun 17, 2026Option exercise+62,581$19.39$1.21M723,239
Matthew C. Kapusta
CEO, Managing Director
Jun 17, 2026Sale(10b5-1 plan)−33,334$45.01$1.50M570,395
Matthew C. Kapusta
CEO, Managing Director
Jun 17, 2026Sale(10b5-1 plan)−11,585$48.65$563.61K558,810
Matthew C. Kapusta
CEO, Managing Director
Jun 17, 2026Sale(10b5-1 plan)−32,581$45.02$1.47M660,658
Madhavan Balachandran
Director
Jun 17, 2026Sale(10b5-1 plan)−5,295$47.08$249.29K49,644
Madhavan Balachandran
Director
Jun 17, 2026Sale(10b5-1 plan)−4,700$43.66$205.20K44,944
Madhavan Balachandran
Director
Jun 17, 2026Sale(10b5-1 plan)−1,690$42.60$71.99K43,254
Madhavan Balachandran
Director
Jun 17, 2026Option exercise+6,390$19.39$123.90K54,939
Madhavan Balachandran
Director
Jun 17, 2026Option exercise+5,295$31.71$167.90K48,549
Madhavan Balachandran
Director
Jun 15, 2026Option exercise+10,000$8.49$84.90K53,254
Madhavan Balachandran
Director
Jun 15, 2026Sale(10b5-1 plan)−10,000$27.85$278.50K43,254
Jeannette Potts
Chief Legal Officer
Jun 15, 2026Sale−5,237$27.67$144.91K133,246
Jeremy P. Springhorn
Director
Jun 11, 2026Sale−1,993$27.06$53.93K43,251
Jack Kaye
Director
Jun 11, 2026Sale−1,993$27.06$53.93K25,996
Madhavan Balachandran
Director
Jun 11, 2026Sale−1,993$27.06$53.93K43,254
Kylie O'Keefe
Chief Customer & Strat Officer
Jun 11, 2026Sale−15,936$27.06$431.23K108,864
Leonard E. Post
Director
Jun 11, 2026Sale−1,993$27.06$53.93K35,494
Rachelle Suzanne Jacques
Director
Jun 11, 2026Sale−1,993$27.06$53.93K33,903
David D. Meek
Director
Jun 11, 2026Sale−1,993$27.06$53.93K39,747
Robert Gut
Director
Jun 11, 2026Sale(10b5-1 plan)−2,726$27.06$73.77K32,259
Jeremy P. Springhorn
Director
Jun 10, 2026Award+7,550––45,244
Jack Kaye
Director
Jun 10, 2026Award+7,550––27,989
Madhavan Balachandran
Director
Jun 10, 2026Award+7,550––45,247
Leonard E. Post
Director
Jun 10, 2026Award+7,550––37,487
Rachelle Suzanne Jacques
Director
Jun 10, 2026Award+7,550––35,896
David D. Meek
Director
Jun 10, 2026Award+7,550––41,740
Robert Gut
Director
Jun 10, 2026Award+7,550––34,985
Robert Gut
Director
Jun 10, 2026Sale(10b5-1 plan)−1,780$26.05$46.37K27,435
Robert Gut
Director
Jun 10, 2026Sale(10b5-1 plan)−3,127$26.03$81.40K29,215
Robert Gut
Director
Jun 10, 2026Sale(10b5-1 plan)−2,645$26.07$68.96K32,342
Robert Gut
Director
Jun 10, 2026Option exercise+2,645$16.04$42.43K34,987
Jack Kaye
Director
Jun 3, 2026Option exercise+2,645$16.04$42.43K23,084
Jack Kaye
Director
Jun 3, 2026Sale(10b5-1 plan)−2,645$30.01$79.38K20,439
Walid Abi-Saab
Chief Medical Officer
May 8, 2026Sale(10b5-1 plan)−20,000$25.00$500.00K169,669

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
12.53%
9M shares short
Days to cover
6.4
At 1M shares a day
Change since last report
-2.5%
From 9M shares
Short volume, 20 days
37.1%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of uniQure's stock actually held short. Settlement fails (shares not delivered on time) peaked at 52,675 shares on Sep 10, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
David D. Meek
Director
Nov 6, 20269,080$192.95KNov 6, 2026Vested shares
Matthew C. Kapusta
Officer, Director, CEO AND MANAGING DIRECTOR
Jul 2, 202621,082$951.93KJul 2, 2026Stock option exercise and sale
Jack Kaye
Director
Jun 30, 202621,167$983.03KJun 30, 2026Stock option exercise pursuant to 10b51 plan
Walid Abi-Saab
Chief Medical Officer
Jun 30, 202630,000$1.39MJun 30, 2026Stock option exercise pursuant to 10b51 plan
Walid Abi-Saab
Chief Medical Officer
Jun 26, 20261,434$67.20KJun 26, 2026Restricted Stock Units Vesting
Matthew C. Kapusta
Officer, Director, CEO AND MANAGING DIRECTOR
Jun 25, 202628,716$1.44MJun 25, 2026Stock option exercise and sale
Matthew C. Kapusta
Officer, Director, CEO AND MANAGING DIRECTOR
Jun 24, 20266,696$334.80KJun 24, 2026Vested Stock from PSU and RSU
Matthew C. Kapusta
Officer, Director, CEO AND MANAGING DIRECTOR
Jun 18, 202641,671$1.93MJun 18, 2026Vested Stock from PSU and RSU
Matthew C. Kapusta
Officer, Director, CEO AND MANAGING DIRECTOR
Jun 17, 2026164,429$7.07MJun 17, 2026Vested Stock from PSU and RSU pursuant to 10b51 plan
Jack Kaye
Director
Jun 17, 20265,295$225.39KJun 17, 2026Stock option exercise pursuant to 10b51 plan
Madhavan Balachandran
Director
Jun 17, 202611,685$526.46KJun 17, 2026Stock option exercise and sale Pursuant to 10b5-1 plan
Jeannette Potts
Officer, CHIEF LEGAL OFFICER
Jun 15, 20265,237$144.89KJun 15, 2026RESTRICTED STOCK UNITS VESTING
Jack Kaye
Director
Jun 11, 20261,993$53.94KJun 11, 2026Restricted stock units vesting
David D. Meek
Director
Jun 11, 20261,993$53.94KJun 11, 2026Restricted stock unit vesting
Leonard E. Post
Director
Jun 11, 20261,993$53.94KJun 11, 2026Restricted stock unit vesting

See a number that looks wrong?